Abstract：Objective: To investigate the expression levels of angiopoietin like protein 8 (ANGPTL8) and CXC chemokine ligand 16 (CXCL16) in serum of patients undergoing total knee replacement, and their correlation with lower extremity deep vein thrombosis. Methods: A total of 110 patients who underwent total knee arthroplasty at our hospital between December 2016 and June 2022 were enrolled. Serum ANGPTL8 and CXCL16 levels were measured by enzyme-linked immunosorbent assay (ELISA) preoperatively and 7 days postoperatively for comparison. Patients were divided into non-deep vein thrombosis (non-DVT) group (n=76) and deep vein thrombosis (DVT) group (n=34) based on whether they developed lower extremity DVT. General characteristics were compared between the two groups. Pearson correlation analysis was performed to examine: 1) the correlation between serum ANGPTL8 and CXCL16 levels, and 2) their association with DVT occurrence. Multivariate logistic regression analysis was conducted to identify risk factors for DVT in TKA patients. Receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive value of serum ANGPTL8 and CXCL16 levels for DVT development. Results: 7 days after the surgery of total knee replacement, Serum ANGPTL8 and CXCL16 were significantly lower than preoperative (t=9.189,5.773, P=0.000) and serum ANGPTL8 and CXCL167d in lower extremity deep veinthrornbosis group was higher than that in non lowere extremity deep vein thrombosis group (t=1.96 1,7.580,1.029,8.095,P=0.052,0.000,0.306,0.000); there were obvious differences in age, hypertension history, operation time, bed rest time and body mass index between lower extremity deep vein thrombosis group and non lower extremity deep vein thrombosis group (P<0.05); the levels of serum ANGPTL8 and CXCL16 were obviously and positively correlated with the occurrence of lower extremity deep vein thrombosis (r=0.728, 0.856, P=0.001, 0.000); there was a obvious positive correlation between serum ANGPTL8 level and CXCL16 level in patients with total knee replacement (r=0.538, P=0.000); serum ANGPTL8, CXCL16, history of hypertension, operation time and bed rest time after operation were the influencing factors of lower extremity deep vein thrombosis in patients undergoing total knee replacement (P<0.05); the AUC predicted by the combination of serum ANGPTL8 and CXCL16 in patients undergoing total knee replacement was 0.986, with a sensitivity of 94.12% and a specificity of 95.37%, which was better than their separate prediction (Zcombination-ANGPTL8=2.193, Zcombination-CXCL16=2.343, P=0.028, 0.019). Conclusion: The levels of serum ANGPTL8 and CXCL16 in patients with total knee replacement 7 days after operation are obviously lower than those before operation, in addition, patients with lower extremity deep vein thrombosis have higher levels of serum ANGPTL8 and CXCL16, the combined detection of the two can better evaluate the occurrence of lower extremity deep vein thrombosis in patients undergoing total knee replacement.
[1] 郭凌飞,杜银桥,张明超,等.Sleeve金属袖套联合MBT假体行膝关节翻修术的早期疗效[J].中国修复重建外科杂志,2019,33(3):302-306. [2] Thacoor A,Sandiford N A.Cryotherapy following total knee arthroplasty:what is the evidence[J].Orthop Surg (Hong Kong),2019,27(1):1-6. [3] 刘建龙,李金勇.下肢深静脉血栓清除临床关注焦点[J].中国普通外科杂志,2022,31(6):705-712. [4] Yuan J,Zhang D,Wang Y,et al.Angiopoietin-like 8 in gestational diabetes mellitus:reduced levels in third trimester maternal serum and placenta,increased levels in cord blood serum[J].Int Endocrinol,2022,1(1):1-9. [5] Mabrouk N,Tran T,Sam I,et al.CXCR6 expressing T cells:Functions and role in the control of tumors[J].Front Immunol,2022,13(1):1-9. [6] Su W,Zhou Y,Qiu H,et al.The effects of preoperative rehabilitation on pain and functional outcome after total knee arthroplasty:a meta-analysis of randomized controlled trials[J].Orthop Surg Res,2022,17(1):1-17. [7] 张麟,凃峰,吕龙,等.全膝关节置换术中止血带不同使用策略对下肢深静脉血栓高危诱发因素的影响[J].华中科技大学学报(医学版),2021,50(5):640-644. [8] Zhang Z,Yuan Y,Hu L,et al.ANGPTL8 accelerates liver fibrosis mediated by HFD-induced inflammatory activity via LILRB2/ERK signaling pathways[J].Adv Res,2022,1232(22):1-16. [9] Hu L,Wei J,Zhang Y,et al.ANGPTL8 is a negative regulator in pathological cardiac hypertrophy[J].Cell Death Dis,2022,13(7):1-14. [10] Meng X,Zou H,Li D,et al.Association of circulating ANGPTL8 levels with renal dysfunction:a case-control study[J].Front Public Healthm,2021,9(1):1-7. [11] Stefanska A,Bergmann K,Krintus M,et al.Serum ANGPTL8 and ANGPTL3 as predictors of triglyceride elevation in adult women[J].Metabolites,2022,12(6):1-10. [12] Li T,Pan J,Chen H,et al.CXCR6-based immunotherapy in autoimmune,cancer and inflammatory infliction[J].Acta Pharm Sin B,2022,12(8):3255-3262. [13] Guan T,Emschermann F,Schories C,et al.Platelet SR-PSOX/CXCL16-CXCR6 axis influences thrombotic propensity and prognosis in coronary artery disease[J].Int Mol Sci,2022,23(19):1-23 [14] Chen Y,Wang Z,Li Q,et al.CXCL16/ERK1/2 pathway regulates human podocytes growth,migration,apoptosis and epithelial mesenchymal transition[J].Mol Med Rep,2022,25(6):1-10. [15] Gregersen I,Ueland T,Holter J C,et al.CXCL16 associates with adverse outcome and cardiac involvement in hospitalized patients with Covid-19[J].Infect,2022,85(6):702-769.
2025, Vol. 31 
冀公网安备13080202000786号